ADVFN US – Market Content Editor
-
Stellar Bancorp tops Q2 earnings forecasts, though revenue slightly trails
Stellar Bancorp, Inc. (NYSE:STEL) posted second-quarter 2025 results on Friday that topped Wall Street earnings expectations, bolstered by stable margins and modest balance sheet growth, though revenue came in just shy of estimates. The Houston-based bank reported net income of $26.4 million, or $0.51 per diluted share, beating analyst projections by $0.06. This marked an…
-
Absci shares tumble 16% after pricing discounted stock offering
Shares of Absci Corporation (NASDAQ:ABSI) dropped sharply on Friday after the company announced a public offering of its common stock at a price significantly below the previous day’s close. The clinical-stage biotech firm, which leverages generative AI in drug discovery, priced its new stock issue at $3.00 per share—well under Thursday’s closing price of $3.51.…
-
Charter shares drop nearly 7% as earnings miss and subscriber losses weigh on results
Charter Communications Inc. (NASDAQ:CHTR) saw its stock tumble 6.8% on Friday after reporting second-quarter earnings that fell short of Wall Street expectations, despite revenue coming in on target. The results highlighted ongoing difficulties in retaining broadband subscribers. The cable and broadband giant reported adjusted earnings per share of $9.18, missing the consensus forecast of $9.58.…
-
Sensient posts steady Q2 results as revenue edges higher, earnings in line
Sensient Technologies Corporation (NYSE:SXT) reported second-quarter financial results on Friday that aligned with Wall Street forecasts, as modest revenue gains and a jump in profitability underscored a solid performance across several business units. Following the earnings report, the company’s shares ticked up 0.20% in pre-market trading. For the quarter, Sensient posted earnings per share of…
-
Sarepta shares drop after EU regulators reject Elevidys gene therapy
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Elevidys, the company’s gene therapy designed to treat Duchenne muscular dystrophy. The CHMP declined to support approval of Elevidys for ambulatory…
-
Booz Allen Hamilton shares rally 4% as Q1 earnings top forecasts
Booz Allen Hamilton Holding Corporation (NYSE:BAH) saw its stock jump 4.24% in pre-market trading Friday after delivering fiscal Q1 2026 results that beat Wall Street expectations, even as revenue slipped slightly year-over-year. The McLean, Virginia-based technology and consulting firm posted adjusted earnings per share of $1.48 for the quarter ended June 30, exceeding analyst estimates…
-
Gorman-Rupp shares climb 3% on record Q2 earnings beat
Gorman-Rupp Company (NYSE:GRC) saw its stock rise more than 3% in pre-market trading Friday after reporting record-breaking second-quarter results that outpaced analyst expectations, fueled by infrastructure-related demand and solid municipal sales. The pump manufacturer reported earnings of $0.60 per share for the quarter, topping the average analyst forecast of $0.57. Revenue hit an all-time high…
-
GrafTech slides over 2% as Q2 earnings come in below expectations
GrafTech International Ltd. (NYSE:EAF) saw its shares drop 2.22% in pre-market trading Friday after reporting second-quarter results that fell short of analyst forecasts, despite delivering its strongest sales volume since Q3 2022. The graphite electrode maker posted an adjusted loss of $0.16 per share, underperforming Wall Street’s estimate of a $0.13 loss. Revenue for the…
-
OneMain Holdings surpasses Q2 forecasts as credit indicators strengthen
On Friday, OneMain Holdings, Inc. (NYSE:OMF) announced second-quarter adjusted earnings that outpaced analyst predictions, supported by enhanced credit metrics and robust loan growth. Following the announcement, the company’s shares climbed 1.48% in pre-market trading. The consumer finance provider reported adjusted earnings per share of $1.45 for the quarter, well above the analyst consensus of $1.23.…
-
Lear Shares Drop Nearly 10% After Q2 Earnings Miss Despite Revenue Beat
Lear Corporation (NYSE:LEA), a leading name in automotive technology, reported second-quarter earnings that fell short of analyst expectations on Friday, even though revenue slightly surpassed forecasts. Following the earnings release, Lear’s stock plunged 9.83% in pre-market trading. The company posted earnings per share of $3.06 for Q2, missing the analyst consensus of $3.26 by 20…